Vanta bioscience Limited has submitted its quarterly compliance certificate to BSE Limited, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026.

Regulatory Compliance Submission

The company submitted the certificate on April 10, 2026, in compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The submission was made by Managing Director Dopesh Raja Mulakala to BSE Limited's Corporate Compliance Department.

RTA Confirmation Certificate

Bigshare Services Private Ltd., the company's Registrar and Share Transfer Agent, issued a confirmation certificate dated April 04, 2026. The RTA confirmed that Regulation 74(5) is not applicable to Vanta Bioscience Limited for the quarter ended March 31, 2026.

Non-Applicability Status

The regulation's non-applicability stems from specific operational circumstances during Q4FY26:

• The entire shareholding of the company is maintained in demat form
• No requests for rematerialisation were received from shareholders during the quarter
• No requests for dematerialisation were received from shareholders during the quarter

Corporate Details

Vanta Bioscience Limited operates from its registered office at Umajay Complex, Rasoolpura, Secunderabad. The company maintains its compliance obligations through Bigshare Services Private Ltd., which serves as its official Registrar and Share Transfer Agent.

The submission ensures the company remains compliant with SEBI's regulatory framework governing depositories and participants, maintaining transparency in its shareholding structure and transfer processes.

Vanta Bioscience Limited has responded to BSE Limited's inquiry regarding recent movement in its share price, confirming compliance with all regulatory disclosure requirements. The company's response, dated 11.03.2026, addresses BSE's clarification request made on 25.02.2026.

Regulatory Compliance Confirmation

The company has affirmed that it has disclosed all material information to BSE Limited that may impact its operations and performance. These disclosures have been made in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, along with applicable circulars, within the stipulated timeframes.

Management's Position on Price Movement

Vanta Bioscience's management has stated that they are not aware of any specific reasons for significant movement in the company's share price. The management emphasized that any price movement is purely market-driven and that the company's management is not connected with the share price fluctuations.

The company has reiterated its commitment to maintaining adherence to compliance requirements under the Listing Regulations and other applicable laws. This response demonstrates the company's proactive approach to regulatory communication and transparency.

Corporate Communication

The clarification was signed by Dopesh Raja Mulakala, Managing Director (DIN: 01176660), and submitted digitally on 11.03.2026. The company requested BSE to take this information on record, completing the regulatory response process for the price movement inquiry.